TY - JOUR
T1 - Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma
T2 - A pilot clinical study
AU - Lencioni, Riccardo
AU - Crocetti, Laura
AU - Petruzzi, Pasquale
AU - Vignali, Claudio
AU - Bozzi, Elena
AU - Della Pina, Clotilde
AU - Bargellini, Irene
AU - Cioni, Dania
AU - Oliveri, Filippo
AU - De Simone, Paolo
AU - Bartolozzi, Carlo
AU - Brunetto, Maurizia
AU - Filipponi, Franco
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Background/Aims: Experimental studies have shown synergy between radiofrequency (RF) ablation and adjuvant chemotherapy in animal tumour models. We aimed to assess safety and efficacy of doxorubicin-eluting bead (DEB)-enhanced RF ablation in the treatment of human hepatocellular carcinoma (HCC). Methods: Twenty patients with single HCC ranging 3.3-7.0 cm (mean, 5.0 cm ± 1.4) showing evidence of residual viable tumour after standard RF ablation underwent intraarterial DEB administration (50-125 mg doxorubicin; mean, 60.2 mg ± 21.8). Follow-up period ranged 6-20 months (mean, 12 months ± 5). Results: No major complication occurred. No deterioration of liver function was observed. The volume of treatment-induced necrosis - as measured on imaging - increased from 48.1 cm3 ± 35.7 after RF ablation to 75.5 cm3 ± 52.4 after DEB administration, with an increase of 60.9% ± 39.0. The enhanced effect resulted in confirmed complete response (CR) of the target lesion in 12 (60%) of 20 patients. Incomplete response with persistence of <10% of initial tumour volume was observed in 6 (30%) of 20 patients, and local tumour progression in 2 (10%) of 20. Conclusions: Intraarterial DEB administration substantially enhances the effect of RF ablation. DEB-enhanced RF ablation is safe and results in a high rate of CR in patients refractory to standard RF treatment.
AB - Background/Aims: Experimental studies have shown synergy between radiofrequency (RF) ablation and adjuvant chemotherapy in animal tumour models. We aimed to assess safety and efficacy of doxorubicin-eluting bead (DEB)-enhanced RF ablation in the treatment of human hepatocellular carcinoma (HCC). Methods: Twenty patients with single HCC ranging 3.3-7.0 cm (mean, 5.0 cm ± 1.4) showing evidence of residual viable tumour after standard RF ablation underwent intraarterial DEB administration (50-125 mg doxorubicin; mean, 60.2 mg ± 21.8). Follow-up period ranged 6-20 months (mean, 12 months ± 5). Results: No major complication occurred. No deterioration of liver function was observed. The volume of treatment-induced necrosis - as measured on imaging - increased from 48.1 cm3 ± 35.7 after RF ablation to 75.5 cm3 ± 52.4 after DEB administration, with an increase of 60.9% ± 39.0. The enhanced effect resulted in confirmed complete response (CR) of the target lesion in 12 (60%) of 20 patients. Incomplete response with persistence of <10% of initial tumour volume was observed in 6 (30%) of 20 patients, and local tumour progression in 2 (10%) of 20. Conclusions: Intraarterial DEB administration substantially enhances the effect of RF ablation. DEB-enhanced RF ablation is safe and results in a high rate of CR in patients refractory to standard RF treatment.
KW - Doxorubicin
KW - Hepatocellular carcinoma
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=46249116195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46249116195&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2008.03.021
DO - 10.1016/j.jhep.2008.03.021
M3 - Article
C2 - 18486261
AN - SCOPUS:46249116195
VL - 49
SP - 217
EP - 222
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 2
ER -